BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on BRILINTA, talking to your doctor, and. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start . 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed.

Author: Tell Faeshakar
Country: Seychelles
Language: English (Spanish)
Genre: Marketing
Published (Last): 12 June 2007
Pages: 477
PDF File Size: 16.48 Mb
ePub File Size: 12.15 Mb
ISBN: 638-5-98213-661-3
Downloads: 86047
Price: Free* [*Free Regsitration Required]
Uploader: Shaktishakar

Your Name Your name is required. Ticagrelor is a P-glycoprotein P-gp substrate and grapefruit is a P-gp inhibitor.

This implies that a dose-related effect of fish oil on warfarin may be possible. Because omega-3 fatty acids inhibit platelet aggregation, caution is advised when icosapent ethyl is used concurrently with anticoagulants, platelet inhibitors, or thrombolytic agents.

Moderate Monitor for increased bleeding if ticagrelor is coadministered with duvelisib. Major Due to the thrombocytopenic effects of vorinostat, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors. Ticagrelor is a P-glycoprotein P-gp substrate and erythromycin is a P-gp inhibitor.

Moderate An additive risk of bleeding may occur when platelet inhibitors are used with agents that brilinnta clinically significant thrombocytopenia including antineoplastic agents, such as lomustine. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein P-gp.

Patients should be instructed to monitor for signs and symptoms of bleeding and to promptly report any bleeding events.

BRILINTA has been shown to reduce the rate of a combined endpoint of brilonta death, myocardial infarction or stroke compared to clopidogrel.

Moderate Increased serum concentrations of dabigatran are possible when dabigatran, a P-glycoprotein P-gp substrate, is coadministered with ticagrelor, a mild P-gp inhibitor.

Although ivacaftor exposure could theoretically be increased when given with a CYP3A inhibitor, ivacaftor; lumacaftor dosage adjustments are not recommended with concomitant use of a mild CYP3A inhibitor such as ticagrelor due to the induction effects of lumacaftor.


Acetaminophen; Butalbital; Caffeine; Codeine: Patients should be instructed to monitor for signs and symptoms of bleeding while taking an SNRI with a platelet inhibitor and to promptly report any bleeding events to the practitioner. In one placebo-controlled, randomized, double-blinded, parallel study, patients receiving stable, chronic warfarin therapy were administered various doses of fish oil supplements to determine the effect on INR determinations.

Although a review of Ginkgo biloba in stated that no known drug interactions exist, spontaneous hyphema has been reported in an elderly male who began taking Ginkgo while stabilized on daily aspirin.

Hypersensitivity reactions including angioedema have been reported. Major Monitor patients closely and promptly evaluate any signs or symptoms of bleeding if betrixaban and platelet inhibitors are used concomitantly.

Since there is an increased risk of subsequent cardiovascular events associated with discontinuation of ticagrelor, if possible, manage bleeding without stopping ticagrelor.

Specific ijsert for dosage adjustments in renal impairment are not nisert it appears that no dosage adjustments are needed. The plasma concentrations of ticagrelor can increase when co-administered with netupitant; the inhibitory effect on CYP3A4 can last for multiple days. The degree of ceritinib inhibition of Packgae is unknown. Minor Coadministration of ticagrelor and simeprevir may result in increased exposure to ticagrelor which may increase the bleeding risk.

P-gp inhibition and renal impairment are the major independent factors that result in increased exposure to dabigatran. Major Avoid coadministration of ticagrelor with voriconazole due to increased plasma concentrations of ticagrelor resulting in an increased risk of dyspnea, bleeding, and other treatment-related adverse reactions.

Maintenance doses of aspirin above mg decreased ticagrelor effectiveness in a clinical trial. John’s Wort, Hypericum perforatum. Administer 90 mg twice daily during the first year after an ACS event. Major Consider the use of a parenteral anti-platelet brrilinta for patients with acute coronary syndrome who require concomitant oxymorphone.


A dose reduction, interruption of therapy, or discontinuation of nintedanib therapy may be necessary.

BRILINTA® (ticagrelor) tablets | Antiplatelet & Heart Attack Treatment

The risk of bleeding may be increased in older patients, patients with a history of bleeding disorders, performance of percutaneous invasive procedures, and concomitant use of medications that increase the risk of bleeding e. Moderate Briliinta used concurrently with platelet inhibitors, inhaled iloprost may increase the risk of bleeding.

Moderate Monitor for packagw of efficacy of ticagrelor during coadministration of ivosidenib; a ticagrelor dose adjustment may be necessary. Moderate An increased risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia, such as antithymocyte globulin. Paritaprevir also inhibits P-gp. Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Ticagrelor is primarily metabolized by CYP3A; ticagrelor and inserr active metabolite are also P-glycoprotein P-gp substrates.

The manufacturer does not recommend daclatasvir dose reduction for adverse reactions.

PDR Search

Ticagrelor has not been studied in patients with moderate or severe hepatic disease or impairment. Coadministration with another strong CYP3A4 inhibitor isnert ticagrelor exposure by 7.

Consider increasing the dose of ticagrelor if necessary. Moderate Monitor for evidence of bleeding if coadministration of dasatinib and ticagrelor is necessary.

Do not start ticagrelor in patients planned to undergo urgent coronary artery bypass graft surgery CABG. Moderate Pentosan is a weak anticoagulant. Caution and close monitoring are advised if these drugs are used together.

Start the discussion

Leave a Reply

Your email address will not be published. Required fields are marked *